Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Robert W. Baird

Robert W. Baird began coverage on shares of Alumis (NASDAQ:ALMS) in a report published on Thursday morning, MarketBeat reports. The firm issued an outperform rating and a $25.00 target price on the stock.

ALMS has been the topic of several other reports. Morgan Stanley started coverage on shares of Alumis in a report on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price objective on the stock. HC Wainwright began coverage on shares of Alumis in a research note on Thursday, October 17th. They issued a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Monday, August 19th. Leerink Partnrs upgraded Alumis to a “strong-buy” rating in a research report on Tuesday, July 23rd. Finally, Leerink Partners started coverage on Alumis in a research note on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $27.50.

Alumis Trading Down 0.1 %

Shares of NASDAQ ALMS opened at $11.31 on Thursday. Alumis has a fifty-two week low of $9.54 and a fifty-two week high of $13.53. The company has a 50-day simple moving average of $11.48.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($21.53). As a group, sell-side analysts expect that Alumis will post -8 earnings per share for the current year.

Hedge Funds Weigh In On Alumis

Institutional investors have recently added to or reduced their stakes in the business. Maven Securities LTD purchased a new stake in Alumis in the second quarter worth approximately $332,000. Millennium Management LLC bought a new position in shares of Alumis during the second quarter valued at about $3,376,000. Towerview LLC bought a new position in Alumis during the 2nd quarter worth approximately $4,123,000. Ally Bridge Group NY LLC bought a new stake in Alumis in the second quarter valued at approximately $8,229,000. Finally, Yu Fan bought a new stake in Alumis during the 2nd quarter valued at $10,502,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.